RBC Stock Recent News

RBC Bearings (RBC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

RBC Bearings (RBC) gains from strength in the Aerospace & Defense business, the Specline buyout and shareholder-friendly policies. Rising operating expenses remain a concern for its profitability.

Helima Croft, RBC Capital Markets global head of commodity strategy, joins 'Closing Bell: Overtime' to discuss oil at 2-month highs, the energy outlook, and hurricane impact.

Tesla price target was cut to $227 from $293 by RBC Capital Market analyst Tom Narayan, saying he was lowering the estimates for the company's robotaxi venture and was allocating a bigger revenue share to service providers like Uber and Lyft. He speaks on "Bloomberg Surveillance.

RBC Capital analysts are urging caution with U.S. small-cap stocks, saying it's best to “stay on the sidelines for now.” In a note, the investment bank highlighted a less promising near-term outlook for small caps, citing several factors.

Strength in the Aerospace/Defense segment augurs well for RBC Bearings (RBC). The company's measures to reward its shareholders are promising.

CHICAGO--(BUSINESS WIRE)--Coeur Mining, Inc.'s (“Coeur” or the “Company”) (NYSE: CDE) Chairman, President and Chief Executive Officer, Mitchell J. Krebs, will participate in the RBC Capital Markets Global Mining and Materials Conference on Thursday, June 13, 2024. The RBC Capital Markets Global Mining and Materials Conference is an invitation-only investment conference. Presentation materials will be made available on the Company's website at www.coeur.com. About Coeur Coeur Mining, Inc. is a U.

PTC stock hit a nine-month high Monday after the European Commission decided against pulling its drug, Translarna, from the market. Translarna has a conditional approval in Europe to treat patients with a muscle-wasting disease known as Duchenne muscular dystrophy, or DMD. Twice — in September and January — the Committee for Medicinal Products for Human Use issued a negative opinion on the PTC Therapeutics (PTCT) drug. But following what PTC previously called "tremendous outcry from the patient and physician community," the European Commission has asked its committee to reexamine its opinion. And, so, "Translarna lives to fight another day," Leerink Partners analyst Joseph Schwartz said in a report to clients. It's rare for the European Commission to not adopt its committee's opinion, RBC Capital Markets analyst Brian Abrahams said in a client note. The news Monday increases the chances Translarna remains on the market in Europe and other jurisdictions, he said. But U.S. approval i

RBC Bearings' (RBC) fourth-quarter fiscal 2024 adjusted earnings increase 16% year over year, driven by higher revenues.